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Abstract
Background: Previous studies showed a differential distribution of the four regulatory subunits of cAMP-
dependent protein kinases inside the brain, that changed in rodent gliomas: therefore, the distribution of these
proteins inside the brain can give information on the functional state of the cells. Our goal was to examine human
brain tumors to provide evidence for a differential distribution of protein kinase A in different tumors.
Methods: The distribution of detergent insoluble regulatory (R1 and R2) and catalytic subunits of cAMP dependent
kinases was examined in pediatric brain tumors by immunohistochemistry and fluorescent cAMP analogues
binding.
Results: R2 is organized in large single dots in medulloblastomas, while it has a different appearance in other
tumors. Fluorescent cAMP labelling was observed only in medulloblastoma.
Conclusions: A different distribution of cAMP dependent protein kinases has been observed in medulloblastoma.
Background
Medulloblastoma (MB) is a tumor originating in the cer-
ebellum, most often in children, peaking around seven
years of age. Several histotypes can be recognized with
different marker and prognosis. Medulloblastoma is
thought to arise from the granule cell precursors, that
during development reside in the external granule cell
layer of the cerebellum. Among the most common mod-
ifications in MB are the presence of an isochromosome
17q (i17q) and disrupted development-related signalling
pathways like Sonic Hehdgehog (SHH) and WNT [1]. It
is therefore urgent to examine MB for anomalies in the
biochemical phenotype, that may represent potential
diagnostic landmarks or therapeutic targets. Until now,
the search for specific mutations has lead to the identifi-
cation of some changes that may be present in a percen-
tage of patients. On the other hand, the functional
dysregulation of intracellular pathways may be a com-
mon trait that deserves attention. The ubiquitous cAMP
second messenger system involves the activation of dif-
ferent proteins, the most common being the cAMP-
dependent protein kinase (PKA), a complex of two
homodimers, that upon binding of two cAMP molecules
to each regulatory subunit, releases the two catalytic
subunits, that in turn phosphorylate their target pro-
teins. In mammalian cells, four regulatory subunits
(R1A, R1B, R2A, R2B) and two catalytic subunits (CA
and CB) are known. The subunits share some common
characteristics, but they differentially mediate a variety
of cell functions, by segregating in subcellular compart-
ments. PKA is involved in regulation of cell proliferation
by acting on transcription factors, for example it may
inhibit proliferation by uncoupling Ras from c-Raf acti-
vation [2]. The correct PKA cascade is necessary for the
functional regulation of D-type cyclins, therefore a
defective cAMP/PKA pathway may induce carcinogen-
esis in neuronal precursors [3]. This event may be influ-
enced and even reverted by modifying the type of PKA
subunit that is preferentially expressed by the cell [4].
Therefore the knowledge of modifications in PKA distri-
bution or activity observed during development or
transformation may be relevant to trace cell fate, being
eventually targeted to modify cell phenotype. Different
cAMP analogs have been already used to specifically
address R1 and R2 in various diseases [5].
In the normal rodent brain, we described a differential
distribution of PKA regulatory subunits, that changes
during development and after chemical insults or surgical
lesions. Our focus was on PKA bound to the cytoskeleton
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can concentrate kinase phosphorylating activity in sub-
cellular microdomains. The four different PKA regulatory
subunits show a different appearance, time course and
localization during rodent development. R1A appears
postnatally and persists for two months in cerebellar
nuclei, while in the archicerebellar granuli it appears
from day 17 [6], a period in which Purkinje cells acquire
their mature phenotype and express R1B [7]. Insoluble
R2A is undetectable in the cerebellum, while R2B is pre-
sent in the granule cells already at birth [8]. In addition, a
different distribution of protein kinase regulatory subu-
nits was observed in tumors of glial origin [9].
In the present paper we explored the possibility that
human medulloblastoma specimens present a distribu-
tion of PKA different from the healthy cerebellar tissue,
by analyzing tissue samples from various tumors.
Methods
All reagents are from Sigma, Milan, Italy, unless other-
wise stated. This study was approved by the Institutional
Ethical Committee. Cases and diagnoses are summarized
in Table 1. All patients were males. The three primitive
medulloblastoma cases were all positive for synaptophy-
sin and negative for GFAP. They were compared with
four other tumors:
- one MB relapse: this case was included in order to
control for the replicability of results after therapy,
- one radio-induced glioblastoma following MB, to
control for the specificity of MB results,
- one supratentorial embryonic tumor with abundant
neuropil and true rosettes (ETANTR), which shares fea-
tures of ependymoblastoma and neuroblastoma, to com-
pare MB data with tumors originating probably from
neural stem cells, different from granule cell precursors
- one extra-axial Ewing’s sarcoma/PNET relapse, to
control for a different primitive neuroectodermal tumor
originating outside the central nervous system (see Tab.
1 for details).
Fresh tissue samples were collected during surgery
and immediately snap-frozen in liquid nitrogen. They
were conserved at -70°C until processing.
Primary cultures
Fresh tissues were dissociated by shaking for 5 min in
0.25% Trypsin, 0.02% EDTA (1 ml/mm
3 tissue), then
inactivated with complete high glucose Dulbecco Modi-
fied Eagle’s Medium (DMEM), containing 10% Fetal
Bovine Serum, 10 μg/ml streptomycin, 10 μg/ml tetracy-
clin, 100 I.U./ml penicillin, 25 μg/ml Plasmocin (InVivo-
gen; Milan, Italy). The suspension was centrifuged at
37°C for 10 min at 1350 rpm. The supernatant was dis-
charged and the pellet resuspended in 10 ml of DMEM.
Cells were seeded for 48 hours, washed 3 times with
PBS, and cultured in DMEM (as above, with only 25 μg/
ml Plasmocin) for 3 weeks before freezing.
Immunohistochemistry
After sectioning at 20 μm with a cryostat, sections were
air-dried at room temperature, fixed for 1 hour in 5%
formalin and incubated in Triton X-100 2% in Phos-
phate Buffered Saline (PBS, 10 mM phosphate, 150 mM
NaCl, pH 7.4) for 30 minutes at 18°C. Alternative fixa-
tion procedures were: 1. one minute in 5% formalin at
37°C; 2. one minute in 5% formalin at 37°C followed by
2% Triton X-100 for 30 minutes at 18°C; 3. 30 minutes
in 2% Triton X-100 at 18°C followed by one minute in
5% formalin, 1% Triton X-100 in PBS at 37°C. The
rationale for using different fixation procedures stems
from the fact that different fixation procedures interfere
with the binding of proteins to membranes or
cytoskeleton.
Sections were washed, dried and incubated overnight
with primary antibodies.
C e l l sw e r et h a w e d ,f i x e di nf o r m a l i na t3 7 ° Cf o r1
minute and then incubated in 2% Triton X-100 in PBS
for 5 minutes. Primary antibodies were incubated
overnight.
The following antibodies were used: R1 (rabbit, sc-907,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:200
on slices, 1:500 on cells; R2 (rabbit, sc-908, Santa Cruz
Biotechnology) 1:200 on brain slices, 1:500 on cells;
PKA catalytic subunit (rabbit, sc-903, Santa Cruz Bio-
technology) 1:40 on slices, 1:200 on cells. The secondary
antibody (anti-rabbit IgG Alexafluor 594 conjugate,
Table 1 Summary of cases
CASE AGE DIAGNOSIS
1 17 months Anaplastic large cell medulloblastoma
2 9 years Medulloblastoma, with focal anaplasia
3 4 years Medulloblastoma
4 14 years Medulloblastoma (at age 4), relapse
Previous chemotherapy, no radiotherapy
5 17 years Frontal glioblastoma following medulloblastoma at age 7 Previous chemotherapy and radiotherapy
6 2 years ETANTR
b = embryonic tumor with abundant neuropil and true rosettes
7 17 years Ewing’s sarcoma (at age 15) relapse, extra-axial Previous chemotherapy and radiotherapy
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Page 2 of 8Molecular Probes, Eugene, OR, USA) was incubated 30
minutes at 37°C (1:200 on tissue, 1:500 on cells). Cell
nuclei were counterstained with bis-benzimide (Sigma).
Controls included: a positive control, mouse brain sec-
tions incubated with each of the above antibodies; nega-
tive controls omitting the primary antibody; for
background staining the cells and tumors were incu-
bated with normal rabbit serum.
For colocalization experiments, after immunohisto-
chemistry, cells or tissue were incubated in the presence
of Alexa 488-cAMP, Alexa 568-cAMP (Molecular
Probes), or 8-thioacetamidofluorescein-cAMP (SAF-
cAMP), which allow the visualization of R1A in the
healthy brain tissue [6-8].
After immunohistochemistry, sections were counter-
stained with hematoxylin-eosin.
A Leica epifluorescence microscope (20×, 40×, 100×
objectives) was used. Images (782 × 582 pixels) were
captured with a color digital camera, using the same
parameters within each experiment.
Contrast was enhanced with Corel Photo Paint by
maximum 10% when necessary, at the same degree in
both images if acquired with different filter sets. Panels
were prepared with Corel Draw 12 (Corel Corporation,
Ottawa, Canada).
Results
Typical specific immounolabelling was present in the
more conventional cold formalin fixation followed by
Triton permeabilization, but the data were replicated
also with the other fixation methods that were tried,
albeit with different final intensities of the labelling, or
with different background. Therefore, the data that will
be presented refer to the former fixation protocol.
PKA R2
The three primitive MB and the MB relapse showed a
moderate-intense labelling, in the form of isolated dots
(Figs. 1B, E, 2B, E and 3A). A similar labelling was pre-
sent also in Ewing’s sarcoma relapse (Fig. 3E), while
GBM was less intensely labelled. ETANTR showed a
more varied types of labelling (Fig. 3B), since the R2
clusters could have different forms, not only round.
PKA R1
T h ea n t i b o d ya g a i n s tR 1d i dn o ts h o wad o t t e dl a b e l -
ling. Only scanty elongated branches were present in
all cases, except in Ewing’s sarcoma, which showed
clustered, finely dotted labelling (Fig. 3C). In the
healthy brain of different species [7,8] as in human
brain (Additional file 1: Fig. S1), we observed that 8-
derivative fluorescently-tagged analogs of cAMP bind
to the same protein clusters that are labelled by anti-
PKA R1A antibodies, therefore we controlled for the
fluorescent cAMP labelling in the same tumors. To
our surprise, in the three primitive MB and in the MB
relapse, the tissue showed numerous isolated small-to-
medium size aggregates labelled by fluorescent cAMP
analogs (Figs. 1A, D, 2A, D). The binding of fluores-
cent cAMP is specific, being abolished by 10 μM8 - B r -
cAMP. These data points to a cAMP binding site
which is different from tho s ep r e s e n ti nt h eh e a l t h y
neurons, since it is not labelled by R1, nor by R2 anti-
bodies (Figs. 1C, F, 2C), while being consistently
labelled in a specific way by cAMP 8-derivatives. These
data suggest that human MB cells present cAMP bind-
ing sites that are not normally present during develop-
ment of granule precursor cells. Fluorescent cAMP
labelling was not observed in Ewing’s specimen, while
very few fine and brilliant clusters were observed in
few cells of ETANTR and GBM tissue, reminiscent of
what is observed in healthy neurons of the rodent
brain. Like in these cells, they do not overlap to R2-
labelled structures.
PKA Catalytic subunit
Catalytic subunit of PKA was present in MB specimens
only, as numerous small, brilliant dots throughout the
tissue (Fig. 2E). In some cases, these structures were
labelled also with fluorescent cAMP (Fig. 2F): this sug-
gests that complex structures containing both PKA cata-
lytic subunit and a peculiar cAMP binding site, are
present in MB tissue.
Autofluorescence
Autofluorescence was present as enhanced background
and some orange/yellow clusters, visible with both green
and red filters, only in patients previously submitted to
radiotherapy (for an example, see Fig. 3D). In every
instance, autofluorescence was clearly distinguishable
from secondary antibodies labelling by its broader emis-
sion spectrum that made it visible with different filter
sets, both when particulate or present as a diffuse
background.
Cell cultures
To compare the present data with PKA R2 distribution
that was observed in glioma models [9], cells obtained
from tumor tissues were plated to obtain primary cul-
tures, albeit MB primary cultures do not maintain some
of the pathways present in the tumour [10]. No viable
cultures were obtained from MB. GBM culture showed
the same R2 clustered distribution restricted to the
Golgi apparatus, as already described [9]. A similar
restricted distribution was present in Ewing’s sarcoma
cultures, while R1 was present in the whole cytoplasm
(Fig. 3F), confirming the presence of this subunit, as
observed in the tissue.
Mucignat-Caretta et al. BMC Cancer 2010, 10:141
http://www.biomedcentral.com/1471-2407/10/141
Page 3 of 8Discussion
The deregulation of signalling pathways is a landmark of
cancer development.
The cAMP pathway may act on cell cycle, by activat-
ing PKA that translocates between subcellular compart-
ments. By modulating the timing and localization of
cAMP production, it is possible to affect cAMP effectors
activation, that in turn act on the RAS/ERK and/or
Hedgehog signalling pathways [11]. Therefore, targeting
cAMP production is a viable strategy for supporting
anticancer chemotherapy.
Several MB cell lines decrease their growth rate and
can be differentiated by increasing cAMP levels [12].
Moreover, in a mouse model of MB, the genetic disrup-
tion of the PACAP gene, whose product activates the
PKA pathway, drives cerebellar granule precursor cells
to transformation and to the development of MB [13].
Different kinds of PKA involvement may be conceived,
since the most common chromosomic alterations in
medulloblastoma affect chromosome 17q and 7 [14], in
which also the genes coding for PKA regulatory subu-
nits R1A, R1B and R2B reside. On the other hand,
Figure 1 Medulloblastoma cases 1 (A to C) and 2 (D to F). A: SAF-cAMP labelling. B: R2 immunolabelling. C: merge of A and B: SAF-cAMP
labelling does not overlap to R2. D: SAF-cAMP labelling. E: R2 immunolabelling. F: merge of D and E: the two signals appear separated.
Bar = 10 μm, 100× objective.
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hog factor, that induces granule cell precursors prolif-
eration: this effect is inhibited by adenylate cyclase
activation [15]. In the cerebellum, the chemokine recep-
tor CXCR4 is a Gi-coupled receptor essential for the
development of cerebellar cortex, that may act on SHH
signalling through the control of cAMP [16]. Note-
worthy, CXCR4 is highly expressed also in desmoplastic
and nodular, but not classic, MB [17]. When its activity
is blocked, and hence cAMP production increases,
medulloblastoma growth is inhibited, an effect similar to
phosphodiesterase blockade [18]. During development,
PKA opposes the effects of Hedgehog proteins and
effectors, therefore PKA can be a reasonable target for
MB with a high Hedgehog activity. PKA activity is
essential to prevent the expression of Hedgehog
Figure 2 Medulloblastoma, case 3.A :S A F - c A M Pl a b e l l i n g .B :R 2i m m u n o l a b e l l i n g .C :m e r g eo fAa n dB ,s h o w i n gt h a tS A F - c A M Pd o e sn o t
overlap to R2. D: SAF-cAMP labelling. E: immunohistochemistry to reveal PKA catalytic subunit. F: merge of D and E: most of SAF-cAMP labelled
structures are labelled also by antibody that reveals PKA catalytic subunit. Bar = 10 μm, 100× objective.
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now detected in PKA genes R1A, R1B, R2B, CA and CB
[19]. This may be due to the lethal effects of PKA muta-
tions, given their widespread presence in every cell. No
mutation is detected also in other proteins acting on
transcription, like SHH, SMO, EN-2 that, similarly to
R2B, are located on chromosome 7q, the most affected
in MB [19].
The present data suggest that immunofluorescence
techniques can be successfully applied to MB samples,
given their low autofluorescence background, which is
caused by accumulation of lipofuscin and other product
of cell metabolism, and often prevents the use of fluor-
escence detection techniques in the brain of older ani-
mals and humans. In this way we could demonstrate
that MB samples are characterized by a distinctive
Figure 3 Immunohistochemistry on different samples. A: MB relapse, R2 immunolabelling, similar to primitive MB specimens, 40× objective.
B: ETANTR, R2 immunolabelling (red). Arrows indicate three structures not seen in MB specimens. 100× objective. C to E: Ewing’s sarcoma
relapse. C and D: same field, 40× objective C: R1 immunolabelling in the form of fine dots; this kind of labelling was not present in MB samples.
D: small autofluorescence granuli, albeit not numerous, were present in this specimen; autofluorescence was not present in primitive MB that did
not undergo therapy. E: R2 immunolabelling, 20× objective. F: primary culture obtained from Ewing’s sarcoma relapse; anti-R1
immunohistochemistry, 40× objective. Bar = 10 μm (B); bar = 25 μm (A, C, D, F); bar = 50 μm (E).
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the cell. While R2 could be detected in all samples, R1
could not be revealed using immunohistochemistry. On
the other hand, MB samples but not the other tumors
studied so far could be labelled with fluorescently-tagged
cAMP, that in the normal brain of different species
binds to clustered R1 subunit of PKA, present only in
some types of differentiated neurons [7]. This observa-
tion suggests that MB present a cAMP-binding protein
that is different, or differentially organised, from that
already known. The present data may be useful for
implementing differential diagnosis tools or to design
potential therapeutic agents.
A further complication is added by the fact that each
MB contains functionally heterogeneous cells, with a
small fraction of them exhibiting stem-like properties
[20]: the possibility exists that these cells show different
signalling pathways dynamics, and hence can be targeted
in a differential way.
Up to now it was postulated that cAMP formation
results in PKA activation: however, the formation of
cAMP-saturated PKA holoenzymes, which are inactive,
has been reported under physiological conditions [21].
Future studies will cast light on the presence of cAMP
and its effects on PKA activity and hence in MB cells
cycling in vivo.
Conclusions
The distribution of PKA regulatory subunits is modified
in different tumors, suggesting that variations in com-
mon intracellular signalling pathways may be useful for
differential diagnosis.
Additional file 1: PKAR1/Alexa594-cAMP colocalization in the
normal brain. FIGURE S1. A section from normal brain (case 4) is
shown, 100× objective, bar = 10 μm. A. immunohistochemistry for PKA
R1, revealed with Alexa594 (red)-conjugated secondary antibody. B. the
same section was then incubated with Alexa488 (green)-tagged cAMP.
The arrows indicate two autofluorescent cells. C. Merge of A and B: the
specific green signal overlaps with red signal.
Abbreviations
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